

Datasheet: MCA6149

BATCH NUMBER 157943

Description:	HUMAN ANTI CD30 (BRENTUXIMAB BIOSIMILAR)
Specificity:	CD30
Other names:	TNFRSF8
Format:	Purified
Product Type:	Monoclonal Antibody
Clone:	cAC10
Isotype:	IgG1
Quantity:	0.2 mg

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Target Species	Human
Product Form	Human IgG1 (kappa) antibody - liquid
Preparation	Purified IgG prepared by affinity chromatography on Protein A
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Human CD30

**External Database
Links**

UniProt:

[P28908](#)

[Related reagents](#)

Entrez Gene:

[943](#)

TNFRSF8

[Related reagents](#)

Synonyms

CD30, D1S166E

Specificity

Human Anti-CD30 antibody, clone cAC10, is a research grade biosimilar of the chimeric monoclonal antibody drug brentuximab. It is a recombinant human IgG1 kappa antibody with variable regions from the therapeutic brentuximab antibody clone cAC10. This product is supplied in a research grade format, i.e. in PBS buffer with preservative; it is not manufactured or formulated in the same way as the therapeutic reference product; it is not coupled to the drug monomethyl auristatin E (MMAE).

Brentuximab vedotin (Adcetris) is an antibody drug conjugate that combines the anti-CD30 antibody (brentuximab) with the anti-mitotic agent MMAE (vedotin). It is approved for the treatment of Hodgkin's lymphoma and systemic anaplastic large cell lymphoma. The brentuximab antibody selectively targets tumor cells expressing the cell membrane protein CD30 and delivers the MMAE, which causes apoptosis by preventing cell cycle progression of the G2 to M phase through disruption of the cytosolic microtubule network, thereby preventing tumor growth and proliferation.

This product is NOT FOR THERAPEUTIC USE.

Purity

>98% by SDS PAGE

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany.

**Health And Safety
Information**

Material Safety Datasheet documentation #10094 available at:
<https://www.bio-rad-antibodies.com/SDS/MCA6149>
10094

Licensed Use

For in vitro research purposes only. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

North & South America	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: antibody_sales_us@bio-rad.com	Worldwide	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: antibody_sales_uk@bio-rad.com	Europe	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: antibody_sales_de@bio-rad.com
----------------------------------	---	------------------	---	---------------	---

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets
'M387778:210720'

Printed on 03 May 2024